2,3 Butanediol
The research report includes specific segments by region (country), by manufacturers, by Type and ... Read More
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Outlook 2023
1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
1.1 Product Overview and Scope of Chemotherapy Induced Peripheral Neuropathy Treatment
1.2 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Type
1.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Calcium Channel α2-delta Ligands
1.2.3 Antidepressants
1.2.4 Opioids
1.2.5 Others
1.3 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Application
1.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Comparison by Application: (2021-2027)
1.3.2 Platinum Agents
1.3.3 Taxanes
1.3.4 Vinca Alkaloids
1.3.5 Others
1.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Estimates and Forecasts
1.4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue 2016-2027
1.4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales 2016-2027
1.4.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Region: 2016 Versus 2021 Versus 2027
2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Competition by Manufacturers
2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Manufacturers (2016-2021)
2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Sites, Area Served, Product Type
2.5 Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Situation and Trends
2.5.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Chemotherapy Induced Peripheral Neuropathy Treatment Players Market Share by Revenue
2.5.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Chemotherapy Induced Peripheral Neuropathy Treatment Retrospective Market Scenario by Region
3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures by Country
3.3.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country
3.3.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures by Country
3.4.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country
3.4.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures by Region
3.5.1 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region
3.5.2 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures by Country
3.6.1 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country
3.6.2 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures by Country
3.7.1 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country
3.7.2 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Analysis by Type
4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2016-2021)
4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2016-2021)
4.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2016-2021)
5 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Analysis by Application
5.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2016-2021)
5.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2016-2021)
5.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Aptinyx Inc
6.1.1 Aptinyx Inc Corporation Information
6.1.2 Aptinyx Inc Description and Business Overview
6.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
6.1.5 Aptinyx Inc Recent Developments/Updates
6.2 Asahi Kasei Pharma Corp
6.2.1 Asahi Kasei Pharma Corp Corporation Information
6.2.2 Asahi Kasei Pharma Corp Description and Business Overview
6.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
6.2.5 Asahi Kasei Pharma Corp Recent Developments/Updates
6.3 Regenacy Pharmaceuticals
6.3.1 Regenacy Pharmaceuticals Corporation Information
6.3.2 Regenacy Pharmaceuticals Description and Business Overview
6.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
6.3.5 Regenacy Pharmaceuticals Recent Developments/Updates
6.4 MAKScientific LLC
6.4.1 MAKScientific LLC Corporation Information
6.4.2 MAKScientific LLC Description and Business Overview
6.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
6.4.4 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
6.4.5 MAKScientific LLC Recent Developments/Updates
6.5 Metys Pharmaceuticals AG
6.5.1 Metys Pharmaceuticals AG Corporation Information
6.5.2 Metys Pharmaceuticals AG Description and Business Overview
6.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
6.5.5 Metys Pharmaceuticals AG Recent Developments/Updates
6.6 Nemus Bioscience Inc
6.6.1 Nemus Bioscience Inc Corporation Information
6.6.2 Nemus Bioscience Inc Description and Business Overview
6.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
6.6.5 Nemus Bioscience Inc Recent Developments/Updates
6.7 PledPharma
6.6.1 PledPharma Corporation Information
6.6.2 PledPharma Description and Business Overview
6.6.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
6.4.4 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
6.7.5 PledPharma Recent Developments/Updates
6.8 Sova Pharmaceuticals Inc
6.8.1 Sova Pharmaceuticals Inc Corporation Information
6.8.2 Sova Pharmaceuticals Inc Description and Business Overview
6.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
6.8.5 Sova Pharmaceuticals Inc Recent Developments/Updates
6.9 DermaXon LLC
6.9.1 DermaXon LLC Corporation Information
6.9.2 DermaXon LLC Description and Business Overview
6.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
6.9.4 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
6.9.5 DermaXon LLC Recent Developments/Updates
6.10 Kineta Inc
6.10.1 Kineta Inc Corporation Information
6.10.2 Kineta Inc Description and Business Overview
6.10.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
6.10.5 Kineta Inc Recent Developments/Updates
6.11 Krenitsky Pharmaceuticals Inc
6.11.1 Krenitsky Pharmaceuticals Inc Corporation Information
6.11.2 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Description and Business Overview
6.11.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
6.11.5 Krenitsky Pharmaceuticals Inc Recent Developments/Updates
6.12 PeriphaGen
6.12.1 PeriphaGen Corporation Information
6.12.2 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Description and Business Overview
6.12.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
6.12.4 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
6.12.5 PeriphaGen Recent Developments/Updates
6.13 Apexian Pharma
6.13.1 Apexian Pharma Corporation Information
6.13.2 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Description and Business Overview
6.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
6.13.4 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
6.13.5 Apexian Pharma Recent Developments/Updates
6.14 WinSanTor
6.14.1 WinSanTor Corporation Information
6.14.2 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Description and Business Overview
6.14.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
6.14.4 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
6.14.5 WinSanTor Recent Developments/Updates
7 Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Cost Analysis
7.1 Chemotherapy Induced Peripheral Neuropathy Treatment Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment
7.4 Chemotherapy Induced Peripheral Neuropathy Treatment Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Chemotherapy Induced Peripheral Neuropathy Treatment Distributors List
8.3 Chemotherapy Induced Peripheral Neuropathy Treatment Customers
9 Chemotherapy Induced Peripheral Neuropathy Treatment Market Dynamics
9.1 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Trends
9.2 Chemotherapy Induced Peripheral Neuropathy Treatment Growth Drivers
9.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Challenges
9.4 Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints
10 Global Market Forecast
10.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Chemotherapy Induced Peripheral Neuropathy Treatment by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Chemotherapy Induced Peripheral Neuropathy Treatment by Type (2022-2027)
10.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Chemotherapy Induced Peripheral Neuropathy Treatment by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Chemotherapy Induced Peripheral Neuropathy Treatment by Application (2022-2027)
10.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Chemotherapy Induced Peripheral Neuropathy Treatment by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Chemotherapy Induced Peripheral Neuropathy Treatment by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Comparison by Application (2021-2027)
Table 3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Covered in This Study
Table 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) of Key Manufacturers (2016-2021)
Table 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Manufacturers (2016-2021)
Table 7. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Chemotherapy Induced Peripheral Neuropathy Treatment Average Price (US$/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Sites and Area Served
Table 11. Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2016-2021) & (K Units)
Table 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2016-2021)
Table 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2016-2021) & (K Units)
Table 19. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2016-2021)
Table 20. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2016-2021)
Table 22. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2016-2021) & (K Units)
Table 23. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2016-2021)
Table 24. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2016-2021) & (K Units)
Table 27. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2016-2021)
Table 30. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2016-2021) & (K Units)
Table 31. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2016-2021)
Table 32. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2016-2021) & (K Units)
Table 35. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2016-2021)
Table 38. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Type (2016-2021)
Table 39. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2016-2021)
Table 40. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million US$) by Type (2016-2021)
Table 41. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Type (2016-2021)
Table 42. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (US$/Unit) by Type (2016-2021)
Table 43. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Application (2016-2021)
Table 44. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2016-2021)
Table 45. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million US$) by Application (2016-2021)
Table 46. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Application (2016-2021)
Table 47. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (US$/Unit) by Application (2016-2021)
Table 48. Aptinyx Inc Corporation Information
Table 49. Aptinyx Inc Description and Business Overview
Table 50. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 51. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 52. Aptinyx Inc Recent Developments/Updates
Table 53. Asahi Kasei Pharma Corp Corporation Information
Table 54. Asahi Kasei Pharma Corp Description and Business Overview
Table 55. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 56. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 57. Asahi Kasei Pharma Corp Recent Developments/Updates
Table 58. Regenacy Pharmaceuticals Corporation Information
Table 59. Regenacy Pharmaceuticals Description and Business Overview
Table 60. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 61. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 62. Regenacy Pharmaceuticals Recent Developments/Updates
Table 63. MAKScientific LLC Corporation Information
Table 64. MAKScientific LLC Description and Business Overview
Table 65. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 66. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 67. MAKScientific LLC Recent Developments/Updates
Table 68. Metys Pharmaceuticals AG Corporation Information
Table 69. Metys Pharmaceuticals AG Description and Business Overview
Table 70. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 71. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 72. Metys Pharmaceuticals AG Recent Developments/Updates
Table 73. Nemus Bioscience Inc Corporation Information
Table 74. Nemus Bioscience Inc Description and Business Overview
Table 75. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 76. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 77. Nemus Bioscience Inc Recent Developments/Updates
Table 78. PledPharma Corporation Information
Table 79. PledPharma Description and Business Overview
Table 80. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 81. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 82. PledPharma Recent Developments/Updates
Table 83. Sova Pharmaceuticals Inc Corporation Information
Table 84. Sova Pharmaceuticals Inc Description and Business Overview
Table 85. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 86. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 87. Sova Pharmaceuticals Inc Recent Developments/Updates
Table 88. DermaXon LLC Corporation Information
Table 89. DermaXon LLC Description and Business Overview
Table 90. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 91. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 92. DermaXon LLC Recent Developments/Updates
Table 93. Kineta Inc Corporation Information
Table 94. Kineta Inc Description and Business Overview
Table 95. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 96. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 97. Kineta Inc Recent Developments/Updates
Table 98. Krenitsky Pharmaceuticals Inc Corporation Information
Table 99. Krenitsky Pharmaceuticals Inc Description and Business Overview
Table 100. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 101. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 102. Krenitsky Pharmaceuticals Inc Recent Developments/Updates
Table 103. PeriphaGen Corporation Information
Table 104. PeriphaGen Description and Business Overview
Table 105. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 106. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 107. PeriphaGen Recent Developments/Updates
Table 108. Apexian Pharma Corporation Information
Table 109. Apexian Pharma Description and Business Overview
Table 110. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 111. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 112. Apexian Pharma Recent Developments/Updates
Table 113. WinSanTor Corporation Information
Table 114. WinSanTor Description and Business Overview
Table 115. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 116. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 117. WinSanTor Recent Developments/Updates
Table 118. Production Base and Market Concentration Rate of Raw Material
Table 119. Key Suppliers of Raw Materials
Table 120. Chemotherapy Induced Peripheral Neuropathy Treatment Distributors List
Table 121. Chemotherapy Induced Peripheral Neuropathy Treatment Customers List
Table 122. Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends
Table 123. Chemotherapy Induced Peripheral Neuropathy Treatment Growth Drivers
Table 124. Chemotherapy Induced Peripheral Neuropathy Treatment Market Challenges
Table 125. Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints
Table 126. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Type (2022-2027) & (K Units)
Table 127. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Type (2022-2027)
Table 128. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 129. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share Forecast by Type (2022-2027)
Table 130. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Application (2022-2027) & (K Units)
Table 131. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Application (2022-2027)
Table 132. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 133. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share Forecast by Application (2022-2027)
Table 134. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Region (2022-2027) & (K Units)
Table 135. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Region (2022-2027)
Table 136. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 137. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share Forecast by Region (2022-2027)
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Chemotherapy Induced Peripheral Neuropathy Treatment
Figure 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Type in 2020 & 2027
Figure 3. Calcium Channel α2-delta Ligands Product Picture
Figure 4. Antidepressants Product Picture
Figure 5. Opioids Product Picture
Figure 6. Others Product Picture
Figure 7. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Application in 2020 & 2027
Figure 8. Platinum Agents
Figure 9. Taxanes
Figure 10. Vinca Alkaloids
Figure 11. Others
Figure 12. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size 2016-2027 (US$ Million)
Figure 14. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales 2016-2027 (K Units)
Figure 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 16. Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Manufacturers in 2020
Figure 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Manufacturers in 2020
Figure 18. The Global 5 and 10 Largest Chemotherapy Induced Peripheral Neuropathy Treatment Players: Market Share by Revenue in 2020
Figure 19. Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 20. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2016-2021)
Figure 21. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region in 2020
Figure 22. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2016-2021)
Figure 23. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region in 2020
Figure 24. U.S. Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. France Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. U.K. Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. India Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Taiwan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Thailand Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Malaysia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Philippines Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Vietnam Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. U.A.E Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2016-2021) (US$ Million)
Figure 48. Sales Market Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Type (2016-2021)
Figure 49. Sales Market Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Application (2016-2021)
Figure 50. Sales Market Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Application in 2020
Figure 51. Revenue Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Application (2016-2021)
Figure 52. Revenue Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Application in 2020
Figure 53. Manufacturing Cost Structure of Chemotherapy Induced Peripheral Neuropathy Treatment
Figure 54. Manufacturing Process Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment
Figure 55. Chemotherapy Induced Peripheral Neuropathy Treatment Industrial Chain Analysis
Figure 56. Channels of Distribution
Figure 57. Distributors Profiles
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Aptinyx Inc Asahi Kasei Pharma Corp Regenacy Pharmaceuticals MAKScientific LLC Metys Pharmaceuticals AG Nemus Bioscience Inc PledPharma Sova Pharmaceuticals Inc DermaXon LLC Kineta Inc Krenitsky Pharmaceuticals Inc PeriphaGen Apexian Pharma WinSanTor